News Digest 13.11.2026 — 20.11.2026
Regulators
Procurement of medical devices exceeding 400 million rubles from SMEs will now count toward the quota under Federal Law No. 223-FZ
The Government of the Russian Federation has amended Decree No. 1352 (dated December 2014), which governs the participation of small and medium-sized enterprises (SMEs) in the procurement of goods, works, and services by certain types of legal entities. Under the new rules, procurements made by entities subject to Federal Law No. 223-FZ—specifically those involving medical devices with a maximum contract price exceeding 400 million rubles, as well as narcotic drugs, psychotropic substances, and their precursors—will now count toward the mandatory SME procurement quota. These changes will take effect on January 1, 2027.
Decree No. 1352 establishes a quota for state-affiliated entities (subject to 223-FZ), requiring them to award at least 25% of their total annual contract volume to SMEs. Of this, at least 20% must be sourced through procurements restricted exclusively to SME participants. Details regarding such contracts must be included in the entities' annual reports. Clause 7 of the regulation lists specific exceptions—procurements that are excluded from the quota calculation—covering areas such as national defense, nuclear energy, natural monopolies, financial services, real estate, energy resources, and certain high-risk or high-tech sectors. Previously, medical devices, narcotic drugs, psychotropic substances, and their precursors were also included in this list of exceptions.
The new amendment allows these specific types of procurements to be counted toward the quota, provided they are sourced from SMEs. This concerns procurement contracts that include the supply of medical devices, their subsequent maintenance, operation (if necessary) throughout their service life, repair, and disposal—provided the initial maximum contract price (IMCP) exceeds 400 million rubles. The new rules will also apply to the procurement of narcotic drugs, psychotropic substances, and their precursors, provided the supplier holds a license under Federal Law No. 61-FZ and complies with the list established by Government Decree No. 681.
Market news
Construction of a medical device manufacturing facility completed in the "Titanium Valley" Special Economic Zone
The company "Otdel Meditsinskoy Tekhniki" (OMT) has completed the construction of a second production facility, spanning over 16,000 square meters, at the "Uktus" site of the "Titanium Valley" Special Economic Zone (SEZ) in the Sverdlovsk Region. The facility has already received its commissioning permit; the company intends to launch the production of medical furniture and consumables for medical equipment by the end of 2026. The total investment in the project will exceed 1.1 billion rubles, with plans to create 185 jobs.
The new facility will house a full-cycle production unit for medical furniture, as well as production lines for disposable electrocardiography (ECG) electrodes and sterile medical tubing for mechanical ventilators. The company is currently preparing for the installation and assembly of its production lines. Currently, OMT manufactures functional medical beds, gurneys, dressing and examination tables, IV stands, and specialized furniture, including items for laboratories and pharmacies. According to regional authorities, the company’s products are used, among other places, in the anesthesiology and intensive care unit of Children’s City Clinical Hospital No. 9 in Yekaterinburg.
In July 2026, at the Innoprom exhibition, OMT signed an agreement to expand its production of medical furniture, consumables, and medical devices at the Uktus site. The additional investment was announced at 300 million rubles. At that time, the company had completed the construction of its first production facility, while a second was in the final stages of development. The total construction costs for both facilities were estimated at 716 million rubles.
Russia Increases Imports of Dental Tomography Scanners Following a Two-Year Decline
Imports of dental tomography scanners into Russia rose by 20.5% in 2025 compared to 2024, reaching 841 units. This follows a decline in shipments during 2023 and 2024, according to the agency BusinessStat. In 2023, 785 dental scanners were imported into Russia—a 28.8% decrease from the previous year—followed by a further 11.1% drop in 2024, to 698 units.
In 2023, the cost of this equipment rose due to the weakening of the ruble; against this backdrop, imports of scanners from Finland fell by a factor of 3.5, while those from South Korea declined by 27%. In 2024, procurement was constrained by high interest rates on loans, alongside a continued decline in shipments from Finland and South Korea.
The market recovered in 2025, though import volumes remain below the 2022 peak, when 1,102 scanners were brought into the country. This growth was supported by a strengthening ruble—which made foreign equipment more affordable—and an increase in the revenues of dental clinics.
The geography of procurement shifted in 2025. Italy moved into the top spot in terms of unit volume, while South Korea and China also strengthened their positions. Meanwhile, the share of imports from Finland—which had been the market leader at the beginning of the period—fell to a negligible level. A portion of the supply was also facilitated through parallel imports via Kyrgyzstan and Turkey.
Gamaleya Center Completes Registration of New Polyvalent COVID-19 Vaccine
The N.F. Gamaleya National Research Center for Epidemiology and Microbiology has completed the registration of a new polyvalent vaccine against SARS-CoV-2, reports the newspaper *Izvestia*, citing the center.
The preparation contains antigens from three variants of the virus: the original Wuhan strain, Delta, and Omicron. These components are intended to provide protection against all known COVID-19 variants, including PJ.2.1.
"We have developed two multivalent vaccines for the prevention of COVID-19, based on virus-like particles, designed for both nasal and parenteral administration. These preparations target multiple genotypes. They are effective not only against all previously identified variants but also against newly emerging ones, as they incorporate several types of proteins—including both surface and capsid proteins, as well as both variable and conserved elements. Consequently, even as strains evolve, the vaccine’s efficacy remains stable—or, at most, experiences only a minor decline," explained Tatyana Grebennikova, head of the Molecular Diagnostics Laboratory at the Gamaleya Center.
The vaccine is ready for use, and the developers are currently seeking partners to launch mass production.
Other
Russian manufacturer IMBIAN has begun developing the country’s first test for synovial calprotectin
Russian developer IMBIAN has announced the start of work on a rapid test for calprotectin in synovial fluid. The test is designed to confirm or rule out a joint endoprosthesis (prosthetic joint) infection within 15 minutes. Currently, no such tests are registered in the Russian State Register of Medical Devices. The company plans to submit the product for registration in December 2027, with a development budget of 8 million rubles.
IMBIAN informed *Vademecum* that active development is scheduled to begin on February 10, 2027, with clinical trials planned for August of the same year and a registration submission set for December. The project is being financed through the company’s own funds.
IMBIAN intends to develop a semi-quantitative immunochromatographic test for calprotectin. It will require a 20 µl sample of synovial fluid, with an analysis time of approximately 15 minutes; results can be read either visually or via a portable reader. The test will categorize results into low, intermediate, and high-risk levels, with an upper threshold of 50 mg/L—consistent with most international studies. The target performance metrics include a sensitivity of approximately 90%, a specificity of around 88%, and a negative predictive value of at least 95%.
To verify its accuracy, the developer plans to conduct a prospective, multicenter study using fresh samples. The study will be benchmarked against the 2021 EBJIS and 2018 ICM international criteria. It will include at least 40 confirmed cases of infection, and the results will be compared directly against alpha-defensin testing and cell count analysis. Specific attention will be paid to the test’s application during surgery, as well as to challenging clinical scenarios—such as periprosthetic fractures, rheumatoid arthritis, and cases involving patients who have recently received antibiotics.
"In the long term, this test is intended to become part of an intraoperative rapid-testing panel, alongside alpha-defensin and C-reactive protein. All three tests would be performed on a single, domestically produced platform. The project has been incorporated into the company’s scientific agenda for 2027," the team at IMBIAN explained.
Gorzdrav and 36.6, in partnership with Yandex, have launched robot-assisted delivery of medications
Pharmacy chains Gorzdrav and 36.6 have teamed up with Yandex to offer robot-based delivery for over-the-counter (OTC) drugs. According to the chains' press office, the service has been available in Moscow since November 11.
Orders can be placed via the 366.ru or gorzdrav.org websites or their respective mobile apps. At checkout, customers can select the "Robot delivery" option. A pharmacist prepares the order and loads it into the robot; the customer then receives a notification once the delivery is underway. The robot’s progress can be tracked on the pharmacy chains' websites or through the Yandex Go app. Upon arrival, the customer simply taps "Open robot" to retrieve their purchase outside their building.
Available items include OTC medications—such as painkillers, antivirals, and allergy relief—as well as cosmetics, dietary supplements, and other pharmacy products. The pharmacy chain’s press office clarified that temperature-sensitive medications are not eligible for robot delivery.
The service is currently being tested in eight Moscow districts: Khamovniki, Danilovsky, Ochakovo-Matveyevskoye, Tverskoy, Aeroport, Zamoskvorechye, Savelovsky, and Arbat. Following the testing phase, there are plans to expand the project to St. Petersburg.
The companies anticipate that this new service will reduce delivery costs by 45%, potentially driving a 30% increase in online orders. Furthermore, robot delivery is expected to be particularly useful during seasonal illness outbreaks, as it helps minimize human contact.
New registered medical devices
We publish a list of new medical devices registered from 11.13.2026 to 11.20.2026
Link to the list: [see table in the attachment]


